Abstract
Volumetric additive manufacturing (VAM) is revolutionizing the field of cell printing by enabling the rapid creation of complex three-dimensional cellular structures that mimic natural tissues. This paper explores the advantages and limitations of various VAM techniques, such as holographic lithography, digital light processing, and volumetric projection, while addressing their suitability across diverse industrial applications. Despite the significant potential of VAM, challenges related to regulatory compliance and scalability persist, particularly in the context of bioprinted tissues. In India, the lack of clear regulatory guidelines and intellectual property protections poses additional hurdles for companies seeking to navigate the evolving landscape of bioprinting. This study emphasizes the importance of collaboration among industry stakeholders, regulatory agencies, and academic institutions to establish tailored frameworks that promote innovation while ensuring safety and efficacy. By bridging the gap between technological advancement and regulatory oversight, VAM can unlock new opportunities in regenerative medicine and tissue engineering, transforming patient care and therapeutic outcomes.